Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA.

Int J Mol Sci. 2013 Jan 22;14(1):2085-103. doi: 10.3390/ijms14012085.

2.

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.

J Ovarian Res. 2014 Apr 9;7:38. doi: 10.1186/1757-2215-7-38.

3.

Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. doi: 10.1007/s00280-010-1334-9. Epub 2010 May 5.

4.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
5.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
6.

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.

Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, Häussler SF, Segerer SE, Fujita N, Dietl J, Engel JB.

Oncol Rep. 2012 Dec;28(6):2023-8. doi: 10.3892/or.2012.2041. Epub 2012 Sep 18.

PMID:
22992944
7.

Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.

Kalayda GV, Wagner CH, Jaehde U.

J Inorg Biochem. 2012 Nov;116:1-10. doi: 10.1016/j.jinorgbio.2012.07.010. Epub 2012 Jul 26.

PMID:
23010323
8.

Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.

Jiang L, Luo RY, Yang J, Cheng YX.

Mol Med Rep. 2013 Feb;7(2):425-30. doi: 10.3892/mmr.2012.1216. Epub 2012 Dec 3.

PMID:
23229441
9.

Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.

Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ.

Pharm Res. 2008 Oct;25(10):2272-82. doi: 10.1007/s11095-008-9621-4. Epub 2008 May 29.

PMID:
18509599
10.

Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.

Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, Fedorocko P.

Neoplasma. 2007;54(2):127-30.

PMID:
17319785
11.

Identification of hepsin and protein disulfide isomerase A3 as targets of gelatinolytic action in rat ovarian granulosa cells during the periovulatory period.

Rosewell K, Al-Alem L, Li F, Kelty B, Curry TE Jr.

Biol Reprod. 2011 Oct;85(4):858-66. doi: 10.1095/biolreprod.111.092072. Epub 2011 Jul 6.

12.

High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

Kozubík A, Horváth V, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Zák F, Mistr A, Turánek J.

Biochem Pharmacol. 2005 Feb 1;69(3):373-83. Epub 2004 Dec 23.

PMID:
15652229
13.

Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.

Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.

J Control Release. 2008 Oct 21;131(2):100-6. doi: 10.1016/j.jconrel.2008.07.017. Epub 2008 Jul 18.

PMID:
18691617
14.

Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.

Aggarwal S, He T, Fitzhugh W, Rosenthal K, Feild B, Heidbrink J, Mesmer D, Ruben SM, Moore PA.

Gynecol Oncol. 2009 Dec;115(3):430-7. doi: 10.1016/j.ygyno.2009.08.031. Epub 2009 Oct 2.

PMID:
19800108
15.

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.

Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.

J Transl Med. 2008 Feb 26;6:9. doi: 10.1186/1479-5876-6-9.

16.

Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.

Jendželovská Z, Jendželovský R, Hiľovská L, Kovaľ J, Mikeš J, Fedoročko P.

Toxicol In Vitro. 2014 Oct;28(7):1259-73. doi: 10.1016/j.tiv.2014.06.011. Epub 2014 Jun 30.

PMID:
24994473
17.

Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.

Arzuman L, Beale P, Yu JQ, Proschogo N, Huq F.

Anticancer Res. 2014 Dec;34(12):7077-90.

PMID:
25503135
20.

Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.

Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U.

Biochem Pharmacol. 2007 Jan 15;73(2):298-307. Epub 2006 Oct 10.

PMID:
17097621
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk